ArticleParasitology research2014
Protective efficacy in chickens of recombinant plasmid pET32a(+)-ADF-3-1E of Eimeria acervulina.
Article in Parasitology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Vaccines against chicken coccidiosis with particular reference to previous decade: progress, challenges, and opportunities.Parasitology research · 2022Review
- Actin depolymerizing factor-based nanomaterials: A novel strategy to enhanceFrontiers in immunology · 2022Article
- A review of Eimeria antigen identification for the development of novel anticoccidial vaccines.Parasitology research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This experiment was conducted to study the protective efficacy of recombinant plasmid pET32a(+)-ADF-3-1E in coccidian-infected breeding chickens. The 7-day-old chickens were randomly divided into five groups: a recombinant plasmid pET32a(+)-ADF-3-1E group, a pET32a(+)-ADF group, a pET32a(+)-3-1E group, a control group, and an infection control group. The chickens were immunized intramuscularly with recombinant plasmid DNA in a dose of 200 μg, respectively, and a booster vaccination was given at the same dosage 1 week later. The peripheral blood T lymphocyte proliferation, serum IgG antibody response, and levels of interleukin 2 (IL-2) and interferon gamma (IFN-γ) were detected, respectively. The chickens were inoculated with 4 × 10(6) Eimeria acervulina-sporulated oocysts (Baoding strain) on the seventh day after the last immunization to evaluate the protective efficiency of the recombinant plasmid DNA. The results showed that the lymphocyte proliferation, serum IgG antibody, and IL-2 and IFN-γ levels in recombinant plasmid DNA group were significantly higher than those in control group (P < 0.01). The lymphocyte proliferation, serum IgG antibody, and IL-2 and IFN-γ levels in pET32a(+)-ADF-3-1E group were significantly higher than those in pET32a(+)-3-1E group and pET32a(+)-ADF group, respectively (P < 0.05). It indicated that the pET32a(+)-ADF-3-1E could produce stronger immune responses. The relative body weight gain rate in pET32a(+)-ADF-3-1E group was 88.36 %, which was significantly higher than that in control group (P < 0.05) and infection control group (P < 0.01). The reductions of oocyst production and lesion scores in pET32a(+)-ADF-3-1E group were 67.88 and 67.13 %, respectively. The oocyst excretion and the lesion score of chickens in pET32a(+)-ADF-3-1E group were lower than those in infection control group, respectively. Anticoccidial index (ACI) value in group immunized with pET32a(+)-ADF-3-1E was 169.82. ACI value of 160-179 was considered as effective. These results demonstrated that the pET32a(+)-ADF-3-1E recombinant plasmid DNA could effectively improve the cellular responses and humoral immune responses of the chickens, and it might provide protection against coccidiosis in chickens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.